Following its 2025 edition, La Marató de 3Cat has announced the allocation of funds to 38 cancer research projects, totalling more than €14 million. Three of these projects will be coordinated by CNAG researchers, who will receive nearly €1 million to advance the prevention, diagnosis, and treatment of this disease.
In the field of colorectal cancer, the CNAG's Structural Genomics Group, led by Dr. Marc A. Martí-Renom, will coordinate a project with Dr. Eduard Batlle (IRB Barcelona) to investigate the mechanisms of metastasis. Concurrently, Dr. Holger Heyn, leader of the CNAG's Single Cell Genomics Group, will collaborate with Dr. Francisco Javier Ros Montañá (VHIO) on the study of tumour T cells in metastatic colorectal cancer treated with immune checkpoint inhibitors.
The third funded project will focus on paediatric cancers, coordinated by Dr. Anna Esteve, head of the CNAG's Functional Genomics team, along with Dr. Sonia-Vanina Forcales Fernández (UB) and Dr. Anna Sola Martínez (IDIBELL). This team will investigate the epigenetic regulation of the NBL2 macrosatellite during development and its reactivation in paediatric cancers.
This support strengthens the collaboration between La Marató and CNAG, reinforcing top-tier research in strategic areas such as the fight against cancer, with the ultimate goal of improving people's health and quality of life.




